Abstract

A tricyclopropylamino acid derivative was prepared via Simmons–Smith cyclopropanation of the corresponding alkene. This transformation was plagued by inconsistent conversions, and the opportunity for the removal of the structurally similar alkene contaminant at this stage and downstream via crystallization was limited. These factors combined to make control of the alkene impurity level in the active pharmaceutical ingredient (API) difficult. A removal strategy was developed that utilized downstream, in-process aminoacetoxylation to convert the alkene impurity to structurally dissimilar compounds that purged during crystallization. Using this protocol, the alkene contaminant in the subsequent intermediates, and thus the API, could be controlled to less than 0.1 area percent.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.